| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/20/2022 | 280.95% | Alliance Global Partners | $9.5 → $4 | Maintains | Buy |
| 05/04/2021 | 1090.48% | Alliance Global Partners | → $12.5 | Initiates Coverage On | → Buy |
| 12/10/2020 | 471.43% | Jefferies | → $6 | Downgrades | Buy → Hold |
| 12/10/2020 | 757.14% | HC Wainwright & Co. | $15.5 → $9 | Maintains | Buy |
| 07/24/2020 | 1423.81% | Jefferies | $12 → $16 | Maintains | Buy |
| 06/19/2020 | 1042.86% | Jefferies | → $12 | Initiates Coverage On | → Buy |
| 12/16/2019 | 1042.86% | Dawson James | → $12 | Initiates Coverage On | → Buy |
| 07/31/2018 | 328.57% | B. Riley Securities | → $4.5 | Initiates Coverage On | → Buy |
| 10/06/2017 | 376.19% | Seaport Global | → $5 | Initiates Coverage On | → Buy |
Pluristem Therapeutics Questions & Answers
The latest price target for Pluristem Therapeutics (NASDAQ: PSTI) was reported by Alliance Global Partners on July 20, 2022. The analyst firm set a price target for $4.00 expecting PSTI to rise to within 12 months (a possible 280.95% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Pluristem Therapeutics (NASDAQ: PSTI) was provided by Alliance Global Partners, and Pluristem Therapeutics maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pluristem Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pluristem Therapeutics was filed on July 20, 2022 so you should expect the next rating to be made available sometime around July 20, 2023.
While ratings are subjective and will change, the latest Pluristem Therapeutics (PSTI) rating was a maintained with a price target of $9.50 to $4.00. The current price Pluristem Therapeutics (PSTI) is trading at is $1.05, which is out of the analyst's predicted range.